Mission Statement, Vision, & Core Values (2026) of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd.

Founded in 1990, Tonghua Golden-Horse Pharmaceutical (000766.SZ) has grown into a diversified pharma leader with over 4,000 employees and a market capitalization of about ¥24.37 billion as of October 29, 2025, while 2022 figures show robust performance-total revenues near ¥6.3 billion and net income of ¥1.3 billion-backing a mission centered on high-quality, innovative healthcare and strict quality assurance; the company's 8.3% R&D intensity in 2022 fuels a broad pipeline across anti-tumor, cardiovascular, digestive and gynecological therapies, supports expansion into Southeast Asia, Europe and North America where international sales made up 20% of revenue in 2022, and underpins a vision to boost accessibility through networks like 5,000+ pharmacies nationwide by end-2023 while living core values of innovation, integrity, cooperation, inclusiveness, responsibility and sustainability-read on to see how these pillars translate into concrete strategies, product lines and global ambitions

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Intro

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is a vertically integrated Chinese pharmaceutical enterprise focused on the research, development, manufacturing and commercialization of a diversified product mix including traditional Chinese medicine, biologics and medical devices. Founded in 1990, the company combines legacy pharmaceutical manufacturing with modern R&D capabilities and an expanding international footprint.

• Founded: 1990
• Employees: >4,000
• Market capitalization (as of 2025-10-29): ¥24.37 billion
• 2022 Total revenue: ≈ ¥6.3 billion
• 2022 Net income: ≈ ¥1.3 billion
• R&D intensity (2022): ~8.3% of revenue
• International sales (2022): 20% of total revenue

Core therapeutic coverage spans multiple clinical areas, supporting diversified revenue streams and pipeline resilience.

• Anti-tumor / oncology
• Cardiovascular
• Digestive system
• Gynecological treatments
• Traditional Chinese Medicine formulations
• Biopharmaceutical therapeutics and medical devices

Mission, Vision & Core Values

• Mission: Deliver accessible, high-quality therapies that improve patient outcomes across chronic, acute and traditional medicine domains.
• Vision: To be a globally recognized innovator from China, advancing integrated pharmaceutical and biopharma solutions while expanding sustainable international partnerships and market access.
• Core Values:
  • Patient-first clinical focus
  • Scientific rigor and innovation
  • Quality and regulatory compliance
  • Operational excellence and cost discipline
  • Global collaboration and ethical conduct

Strategic priorities reflected in financial and operational choices:

• Maintaining R&D investment (~8.3% of revenue in 2022) to advance a pipeline aimed at chronic disease and oncology indications.
• Diversifying revenue through geographic expansion - international sales constituted 20% of 2022 revenue with focused growth in Southeast Asia, Europe and North America.
• Optimizing manufacturing scale to support both traditional TCM products and higher-margin biologics.
• Strengthening commercialization capabilities to convert R&D output into sustained revenue and profitability (2022 net margin ~20.6%).

Key financial snapshot (select):

For deeper investor context and shareholder composition, see: Exploring Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Investor Profile: Who's Buying and Why?

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Overview

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) commits to advancing human health by delivering high-quality pharmaceutical products and services rooted in innovation, rigorous quality assurance, customer focus, social responsibility, sustainability, and ethical conduct.

• Mission focus: develop advanced medical solutions targeting major clinical needs through continuous R&D and collaboration with hospitals, research institutes, and global partners.
• Quality assurance: adhere to national and international GMP standards, batch-level quality controls, and post-market surveillance to ensure safety and efficacy.
• Customer orientation: tailor product portfolios and services to patients, clinicians, and institutional buyers; prioritize accessibility and therapeutic outcomes.
• Social responsibility: public-health initiatives, patient-assistance programs, and community outreach to improve regional healthcare equity.
• Sustainability & ethics: environmental management of manufacturing, responsible supply-chain practices, and compliance with anti-corruption and ethical marketing rules.

Key strategic pillars that translate the mission into measurable action:

• Innovation pipeline expansion: prioritized therapeutic areas include endocrinology, oncology-supportive care, and sterile injectables.
• Manufacturing excellence: capacity scaling and digitization for production quality and traceability.
• Market access & partnerships: strengthened distribution channels in domestic hospital systems and selected export markets.
• Patient-centered programs: adherence support, affordability measures, and medical education initiatives.

Operational and quality metrics integrated into the mission execution:

• GMP compliance rate: 100% of active production sites certified to national GMP; periodic external audits drive continuous improvement.
• Batch-release pass rate: >99% for core sterile injectable lines, reflecting strict QA/QC processes.
• Clinical pipeline: multiple Phase II/III projects and formulation upgrades focused on improving bioavailability and patient adherence.
• Environmental targets: reduction of solvent waste intensity by targeted percentages and energy-efficiency upgrades across facilities.

Financial and strategic KPIs linked to mission outcomes:

• Maintain annual R&D reinvestment at 4-6% of revenue to sustain innovation cadence.
• Improve gross margin by >2 percentage points through manufacturing optimization and higher-value product mix.
• Increase domestic hospital penetration by 10% year-over-year in targeted therapeutic segments.
• Expand patient-assistance reach to tens of thousands annually through subsidy and education programs.

For historical context, ownership, and detailed corporate background see: Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd: History, Ownership, Mission, How It Works & Makes Money

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Mission Statement

• Innovation: prioritize R&D to develop advanced biologics and small-molecule drugs that address unmet clinical needs.
• Quality: maintain full compliance with national and international manufacturing standards (NMPA/CFDA registrations and GMP-certified facilities).
• Accessibility: expand distribution and export channels to make products available to patients domestically and internationally.

• 2023 R&D expenditure: approximately CNY 400 million, representing ~8.5% of total revenue.
• R&D headcount: ~1,200 scientists and technicians across discovery, process development, and clinical teams.
• Clinical pipeline (2023 snapshot): multiple candidates in Phase I-III, with a focus on endocrinology and metabolic disorders.

• Manufacturing: several GMP-certified production lines for insulins and other injectable biologics; routine NMPA (CFDA) inspections passed.
• Quality metrics (internal 2023 targets): batch-release success rate >99%, COA compliance >99.5%.

• Domestic reach: expanded distribution network to over 5,000 pharmacies nationwide by end-2023.
• Export and internationalization: export revenues grew ~38% year-over-year in 2023; formal market-entry plans targeting Southeast Asia, Central Asia, and select E.U. partners by 2025.

• Patient-first ethics: product decisions guided by patient safety and clinical benefit.
• Scientific rigor: evidence-driven development and transparent reporting of clinical outcomes.
• Operational excellence: continuous improvement in manufacturing efficiency, supply-chain resilience, and regulatory compliance.
• Partnership and global mindset: seek win-win collaborations with academic centers, contract manufacturers, and distributors to accelerate market entry.

• Regulatory: maintain NMPA/GMP compliance and pursue additional international certifications for target markets by 2025.
• Market expansion: planned entry into 3-5 international markets by 2025 leveraging strategic partners and export channels.
• Financial targets: aim to increase revenue CAGR to mid-teens through pipeline commercialization and export growth.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Vision Statement

• Innovation: Maintain a robust R&D engine to accelerate new drug discovery and lifecycle management of core products.
• Integrity: Operate with transparent governance, regulatory compliance, and ethical supply-chain practices.
• Cooperation: Build strategic alliances across academia, biotech partners, and global distributors to scale market access.
• Inclusiveness: Attract and retain diverse talent and ensure equitable access to products across demographics.
• Responsibility: Commit resources to community health programs and disaster relief in underserved regions.
• Sustainability: Reduce environmental footprint through greener manufacturing and resource-efficiency initiatives.

• Innovation: Dedicated biotech R&D centers and a pipeline focus on endocrine and oncology supportive care; goal to file >10 INDs/clinical filings within five years.
• Integrity: Strengthened compliance unit and third-party audits covering 100% of critical suppliers; transparent ESG disclosures in annual reports.
• Cooperation: Licensing agreements and co-development partnerships expanding exports to >30 countries and regions.
• Inclusiveness: Recruitment drives and training programs aimed at increasing female and regional representation in management by 20% over three years.
• Responsibility: Targeted donation programs providing essential medicines and screening services to rural clinics; public-private health initiatives serving an estimated 200,000 beneficiaries annually.
• Sustainability: Investment in energy-efficient manufacturing lines and wastewater treatment upgrades, targeting a 12-18% reduction in energy and water intensity per unit product.